JonathonBrettCohenMD

PubMed

• The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
  James R Cerhan, Matthew J Maurer, Brian K Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R C...> ;American Journal of Hematology. 2024 Mar 1
• Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
  Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
• Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzu...
  Matthew J Maurer, Carla Casulo, Melissa C Larson, Thomas M Habermann, Izidore S Lossos, Yucai Wang, Loretta J Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin...> ;Haematologica. 2023 Nov 30
• Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
  Narendranath Epperla, Lei Feng, Nirav N Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M Stephens, Catherine J Lee, Thomas Ollila, Geoffrey Shouse, Alexey V Danilov, Ke...> ;Journal of Hematology & Oncology. 2023 Nov 9
• Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20B Cell Lymphoma.
  Ian W Flinn, Jessica Sachs, Benjamin Exter, Ann Ranger, Patricia Harris, Francis Payumo, Rajneesh Nath, Mehdi Hamadani, Jason R Westin, Veronika Bachanova, Munoz, J., ...> ;Transplantation and Cellular Therapy. 2024 Feb 1
• Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
  Colleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B Cohen, Thomas Habermann...> ;British Journal of Haematology. 2024 Jan 1
• 2 citations
  Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
  Stephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P Collins, Jonathon B Cohen, Jan Paul de Boer, Joh...> ;Blood Advances. 2023 Oct 24
• A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
  Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
• SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
  Rahul K Nayak, Drew Gerber, Chen Zhang, Jonathon B Cohen> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
• Recent approval of pirtobrutinib for mantle cell lymphoma.
  Jonathon B Cohen> ;Clinical Advances in Hematology & Oncology. 2023 Aug 1
• 1 citations
  A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
  Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar, I Brian Greenwell, Brian T Hess, Krista M Isaac, Craig A Portell, Alex Mejia Garcia...> ;Blood Advances. 2023 Jul 11
• 21 citations
  Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
  Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel, Toby A Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S Tam, Nirav N Sh...> ;The New England Journal of Medicine. 2023 Jul 6
• 9 citations
  Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
  Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen, Tamara K Moyo, Thomas Ollila, Brian Hess, Ishan Roy, Robert Ferdman, Jieqi Liu, Sa...> ;Blood Advances. 2023 Jun 27
• 3 citations
  Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
  Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N Gerson, Stefan K Barta, Max J Gordon, Alexey V Danilov, Natalie S Grover, Stephanie Mathews, Made...> ;Blood Advances. 2023 Jun 13
• TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.
  Max J Gordon, David A Bond, Adam S Kittai, Neda Amirmokhtari, Abigail Steinbrunner, Allison Huffman, Victor Orellana-Noia, Geoffrey Shouse, Jonathon B Cohen, Tycel Phi...> ;Haematologica. 2023 Nov 1
• 2 citations
  Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
  Juan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, Melissa C Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M Habermann, Peter Martin, Jennifer R Chapman, Chri...> ;Blood. 2023 Apr 13
• 4 citations
  A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
  Walter Hanel, Polina Shindiapina, David A Bond, Yazeed Sawalha, Narendranath Epperla, Timothy Voorhees, Rina Li Welkie, Ying Huang, Gregory K Behbehani, Xiaoli Zhang, ...> ;Cancers. 2023 Feb 24
• 2 citations
  Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
  Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K Moyo, Nishitha Reddy, Julia Sheets, David M Weiner, Praveen Ramakrishnan Geethakumar...> ;Blood Advances. 2023 Jan 10
• 3 citations
  Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
  Chang, A., Akhtar, A., Lai, L., Orellana-Noia, V., Linderman, S., McCook-Veal, A., Switchenko, J., Saini, M., Valanparambil, R., Blum, K., Allen, P., Lechowicz, M., Ro...> ;Cancer Research Communications. 2022 Dec 1
• MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN...
  Jonathon B Cohen, Nirav N Shah, Alvaro J Alencar, James N Gerson, Manish R Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L Lewis, Timothy Fenske, Cather...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• EXABS-205-MCL Immunotherapeutic Options for Patients with MCL Who Progress on BTK Inhibitors.
  Jonathon B Cohen> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 27 citations
  Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
  Chang, A., Akhtar, A., Linderman, S., Lai, L., Orellana-Noia, V., Valanparambil, R., Ahmed, H., Zarnitsyna, V., McCook-Veal, A., Switchenko, J., Koff, J., Blum, K., Ay...> ;Journal of Clinical Oncology. 2022 Sep 10
• 1 citations
  Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
  Jason T Romancik, Zhengjia Chen, Pamela B Allen, Edmund K Waller, Kelly Valla, Amanda Colbert, Cecilia Rosand, Alexandra F Palmer, Christopher R Flowers, Jonathon B Cohen> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Dec 1
• Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
  Danny Luan, Tolulope Fatola, Ahmed Toure, Christopher R Flowers, Brian Link, Jonathan W Friedberg, Jonathon B Cohen, Brad Kahl, Izidore S Lossos, Loretta Nastoupil, Ma...> ;Blood Advances. 2022 Aug 9
• 2 citations
  A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus.
  Christopher Dittus, Natalie Grover, Tarsheen Sethi, Jonathon B Cohen, Alfredo Voloschin, Janhvi Rabadey, Xianming Tan, Anne Beaven, Steven I Park> ;Ejhaem. 2022 Aug 1
• Join now to see all

Journal Articles

• Intrathecal Central Nervous System Prophylaxis in Patients with Diffuse Large B-cell Lymphoma at an Academic Healthcare System  
  Jonathon Cohen, MD, Clinical Lymphoma, Myeloma, & Leukemia

Abstracts/Posters

• Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Expert Perspectives on the Role of BTK Inhibitors in CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Aggressive Lymphomas 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Aggressive Lymphomas 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Join now to see all